Related Experiment Videos
Oncogene activation in pituitary tumors.
1Cedars-Sinai Research Institute-UCLA School of Medicine, Los Angeles, CA 90048, USA.
Brain Pathology (Zurich, Switzerland)
|June 21, 2001
Summary
Pituitary tumors are often benign adenomas driven by oncogenes like gsp, ccnd1, and PTTG. These genes promote cell proliferation, GH secretion, and tumor vascularity, contributing to pituitary tumor development.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Pituitary tumors represent 10% of intracranial neoplasms, predominantly benign monoclonal adenomas.
- Key oncogenes, including gsp, ccnd1, and PTTG, are frequently implicated in pituitary tumorigenesis.
Purpose of the Study:
- To review the roles of specific pituitary oncogenes (gsp, ccnd1, PTTG) in the development and progression of pituitary tumors.
- To elucidate the molecular mechanisms underlying pituitary tumor formation driven by these oncogenes.
Main Methods:
- Review of existing literature on pituitary oncogenes and tumorigenesis.
- Analysis of genetic alterations (mutations, overexpression, amplification) in pituitary tumors.
- Investigation of cellular pathways affected by oncogene activation.
Main Results:
- The gsp oncogene, mutated in ~40% of GH-secreting tumors, leads to persistent cAMP-PKA-CREB pathway activation.
- Cyclin D1 (ccnd1) is overexpressed and its gene amplified in some pituitary tumors.
- Pituitary tumor transforming gene (PTTG) is highly expressed and implicated in tumor vascularity, proliferation, and aneuploidy, while also inducing apoptosis via p53.
Conclusions:
- Specific oncogenes play critical roles in pituitary tumor development through diverse molecular mechanisms.
- PTTG is a significant oncogene involved in multiple aspects of pituitary tumorigenesis, including angiogenesis and cell cycle regulation.
- Further research using advanced models is needed to fully understand pituitary tumor pathogenesis.